Baidu
map

Exp Hematol:急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系

2021-11-28 MedSci原创 MedSci原创

化疗后 BM 中的 NK/CD4CM 比率与随后中性粒细胞恢复的时间显着相关(Spearman's ρ = -0.723,p < 0.001,FDR < 0.01)。

化疗引起的骨髓 (BM) 损伤是急性髓系白血病 (AML) 发病率和死亡率的重要原因。为了在化疗损伤后实现血液学恢复,BM 中残留的正常造血干/祖细胞 (HSPC) 需要补充成熟的血细胞。HSPC 行为受到其微环境(即所谓的 HSPC 生态位)的严格调控。许多研究中的发现意味着淋巴细胞亚群可能在 AML 化疗后的造血恢复中发挥作用,但淋巴细胞亚群如何受到强化化疗的影响仍然未知。在这里,国外研究团队评估了评估了先天和适应性免疫子集组成的再生BM诱导化疗后(17天)及相关血液AML的复苏,并将其与 AML 的血液学恢复相关联。
 
 
研究人员在开始缓解诱导化疗(7+3 方案的阿糖胞苷和蒽环类化疗)后 17 天(范围 16-19)收集 AML 患者(平均:58 岁,范围:20-75 岁)的 BM 抽吸物。在获得书面知情同意后,通过同种异体移植捐赠者的抽吸获得对照骨髓(平均:64.8 岁,范围:47-78 岁)。伊拉斯谟医学中心(荷兰)机构审查委员会根据赫尔辛基宣言批准在知情同意的情况下使用人体样本。
 
从 BM 抽吸物中分离出单核细胞 (MNC)。随后,BM 抽吸物进行离心并用 PBS+0.5% FCS 洗涤一次。接下来,BM 抽吸物被分成两部分,并用以下两种抗体混合物中的一种染色:一种混合物 (1) 确定单核细胞、B 细胞、T 细胞、NK 细胞、B 细胞的频率,另一种混合物 (2) ) 以确定初始和记忆 T 细胞亚群的频率。对于 (1),使用 CD14和包含 CD45、CD3、CD16/CD56 和 CD19 的多测试混合物,而对于 (2),使用CD45 , CD45RA , CD3 , CD4 、CD8和 CD62L。
 
 
图 1 :AML 强化化疗后恢复后 BM 免疫亚群的组成
图 2: CD4CM T 和 NK 细胞的频率与 AML 化疗后中性粒细胞的恢复有关。
 
结果显示,T 细胞,特别是 CD4 中央记忆 (CD4CM) T 细胞亚群,在化疗后在 BM 中显着富集,表明细胞的相对化学抗性为全身病原体提供长期记忆。相比之下,B 细胞和其他造血亚群被耗尽。CD4CM T 细胞亚群的较高频率与造血恢复延迟有关,而 NK 细胞的较高频率与中性粒细胞计数的较快恢复有关。
 
研究表明,化疗后 BM 中的 NK/CD4CM 比率与随后中性粒细胞恢复的时间显着相关(Spearman's ρ = -0.723,p < 0.001,FDR < 0.01)。这些数据为化疗损伤后的免疫重建提供了新的见解,并暗示 CD4CM 和 NK 细胞之间的平衡是 AML 造血恢复的潜在预测因素。预计这些发现将促使未来对特定免疫亚群在 HSPC 恢复中的作用进行调查,并指导未来支持治疗的潜在定制。
 
原始出处:
Kenswil KJG,Pisterzi P,Feyen J,et al.Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia.[J].Exp Hematol,1970,:.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-04-01 ms7000001055015876

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1207977, encodeId=89f1120e97795, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9af96571446, createdName=ms7000001055015876, createdTime=Fri Apr 01 22:28:14 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822118, encodeId=e234182211859, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Jun 11 16:13:39 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398238, encodeId=3ebb139823872, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466328, encodeId=a4a914663284e, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Tue Nov 30 06:13:39 CST 2021, time=2021-11-30, status=1, ipAttribution=)]

相关资讯

J Clin Oncol:乳腺癌化疗后大脑认知功能减退的罪魁祸首

化疗脑:20%~40%的乳腺癌患者化疗后可出现记忆力、注意力、思维等大脑认知功能减退,可能持续至康复期并干扰日常生活技能和生活质量。在化疗前预测化疗后有脑功能减退风险的乳腺癌患者,将有助于改善患者治疗

Clin Cancer Res:曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比

曲妥珠单抗联合内分泌治疗作为激素受体阳性、HER2阳性的转移性乳腺癌的一线方案的效果不劣于曲妥珠单抗联合化疗

JCO:派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响

CPS≥10分的食道鳞状细胞癌患者采用派姆单抗单药或化疗维持治疗的健康相关生活质量无明显差异

Front Oncol: 化疗对I期鼻咽癌患者的预后影响

研究表明,在放疗的基础上添加化疗并不能改善I期鼻咽癌患者的预后。放疗仍是该类患者的推荐治疗手段。

ESMO Open:接or不接?对于抗癌治疗患者,BNT162b2 COVID-19疫苗效果如何?

抗肿瘤治疗患者对BNT162b2新冠mRNA疫苗的体液免疫反应降低,尤其是接受化疗或利妥昔单抗的患者。

Eur Urol:转移去势抵抗性前列腺癌中,激素治疗与化疗获益的预测性基因组生物标志物调查

新的激素疗法(NHTs),如阿比特龙和恩扎鲁胺,以及基于紫杉类药物的化疗,是治疗转移去势抵抗性前列腺癌(mCRPC)的常用系统疗法。

拓展阅读

【BCJ】金洁/王华锋教授团队报道NPM1突变初治AML患者的共突变特征及预后意义

浙大一院血液科金洁/王华锋教授白血病团队开展一项单中心回顾性研究,评估了共突变特征对携带 NPM1 突变的 AML 患者(不包括APL)的治疗和预后意义。

【JCO Oncol Pract】AML伴高白细胞血症的预后及影响因素

为了分析AML患者出现高白细胞血症的结局,确定特定预测标志物的权重以及改善结局的最佳实践,帮助指导管理和改善早期死亡率。

【BMT】首次CR期AML的GVHD预防对比:CSA或TAC联合PTCy+MMF

因此EBMT的急性白血病工作者开展一项回顾性研究,在一个大型同质化CR1 AML患者队列中比较了PT-Cy联合MMF及CSA或TAC用于GVHD预防的结果。

Leukemia | III 级肥胖增加急性髓系白血病年轻患者的早期死亡率和降低生存率

该研究旨在确定肥胖与AML预后的关系,研究结果显示肥胖 III 级 (BMI ≥ 40 kg/m2) AML 患者具有更高的早期死亡风险和更差的 OS。

J HEMATOL ONCOL | ASH 2023:Menin抑制剂在复发或难治性急性髓系白血病中的突破性进展

该篇文章报道了多个Menin抑制剂的最新的研究进展,Menin抑制剂作为一种新型靶向治疗药物,在复发或难治性急性髓系白血病患者中展现出令人鼓舞的疗效和安全性。

Blood Cancer J | NPM1 突变急性髓系白血病患者的共突变特征、预后及治疗策略

该研究旨在探讨NPM1突变急性髓系白血病患者的共突变特征,并评估其对预后的影响,研究发现强调了共突变分析在 NPM1 突变急性髓系白血病患者风险分层和治疗决策中的重要性。

2024 NICE 技术鉴定指南:伊伏西尼联合阿扎胞苷治疗未经治疗的 IDH1 R132 突变急性髓系白血病 [TA979]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-06-05

CACA 成人急性髓系白血病整体综合管理指南

中国抗癌协会(CACA,Chinese Anti-cancer Association) · 2024-03-14

成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)

中华医学会血液学分会白血病淋巴瘤学组 · 2024-01-01

中国复发难治性急性髓系白血病诊疗指南(2023年版)

中华医学会血液学分会白血病淋巴瘤学组 · 2024-01-01

FDA指导文件:急性髓系白血病开发用于治疗的药物和生物制品

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2022-10-17

Baidu
map
Baidu
map
Baidu
map